



March 13, 2015

Radius Health to Present at the Bank of America Merrill Lynch Smid Cap Conference

WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that its Chief Scientific Officer, Gary Hattersley, will present at the Bank of America Merrill Lynch Smid Cap Conference on March 18, 2015 at 8:00 a.m. EDT at the Four Seasons Hotel, Boston, Massachusetts.

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. The company's lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com.

CONTACT: Investor Relations

Barbara Ryan

Partner

Clermont Partners

203-274-2825

bryan@radiuspharm.com